Plain-English translation of NCT06733246 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a device called Ceretrieve, which uses suction to remove blood clots from arteries in the brain during an acute ischemic stroke. The device is designed to restore blood flow to the brain quickly after a stroke occurs. Researchers want to confirm that this treatment is safe and effective for patients who qualify.
When a blood clot blocks an artery in the brain, it causes a stroke and brain damage. This treatment aims to remove the clot quickly to restore blood flow and reduce long-term disability.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the Ceretrieve device treatment as part of your acute stroke care within 24 hours of your symptoms starting. The procedure is performed during angiography, where doctors use imaging to guide the device through your blood vessels to the clot. You will be enrolled in this single-arm study, meaning all eligible patients receive the same treatment, and you'll have follow-up evaluations to monitor your recovery and outcomes.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
Germany
Ceretrieve Ltd.
Enrollment target
~132 participants
Started
November 2024
Primary completion
May 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hilla Hilla Ben-Ezra, Ms.
Ceretrieve Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.